Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tysabri Marketing Unaffected By Proposed Risk Management Plan

Mar 08 2006

• By Danielle Foullon, Kathryn Phelps, and Jonathan Block

Related Content

Tysabri Revised RiskMAP Would Have Mandatory Patient/Physician Registry Enrollment

Mar 07 2006

Tysabri Return To Market For First-Line Use In Relapsed MS Supported By Slim Majority

Mar 08 2006

Tysabri Risk Management Plan Needs Strengthening, FDA Says

Mar 06 2006

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window